Skip to main content
SpringerLink
Log in

Targeted Therapies for Neuroendocrine Neoplasms

  • Chapter
  • First Online:
Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances

  • 1326 Accesses

Abstract

Neuroendocrine tumors are rare but have increased in incidence over the last several decades. Significant advances in the understanding of the molecular biology of these tumors have led to new treatment options. Somatostatin analogs were the first targeted therapy for neuroendocrine tumors. Several other targeted therapies have subsequently established a role in the management of these diseases. In this chapter, we will describe currently available targeted therapies for neuroendocrine tumors and review the clinical status of promising investigational therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303. doi:10.1016/j.ccr.2014.02.025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, Eckloff BW, Wieben ED, Wu Y, Cunningham JM, Nagorney DM, Gilbert JA, Ames MM, Beutler AS. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123(6):2502–8. doi:10.1172/JCI67963. 67963 [pii].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Caplin M. Phase III trial results favour lanreotide therapy. In: Patients with gastroenteropancreatic neuro-endocrine tumours. Amsterdam: European Society of Medical Oncology (ESMO); 2013.

    Google Scholar 

  4. Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Manzano Mozo JL, Sevilla I, Duran I, Salazar R. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013;49(18):3780–7. doi:10.1016/j.ejca.2013.06.042.

    Article  CAS  PubMed  Google Scholar 

  5. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2963–8. doi:JCO.2011.40.3147 [pii] 10.1200/JCO.2011.40.3147.

    Article  CAS  Google Scholar 

  6. Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22(1):1–9. doi:10.1530/ERC-14-0360.

    Article  CAS  PubMed  Google Scholar 

  7. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015;22(3):431–41. doi:10.1530/ERC-15-0002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):451–8.

    Article  Google Scholar 

  9. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95(9):1148–54. doi:6603419 [pii] 10.1038/sj.bjc.6603419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Eads JR, Meropol NJ. A new era for the systemic therapy of neuroendocrine tumors. Oncologist. 2012;17(3):326–38. doi:10.1634/theoncologist.2011-0356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Feyrter F. Über diffuse endocrine epitheliale Organe. Leipzig: Barth; 1938.

    Google Scholar 

  12. Grande E, Capdevila J, Castellano D, Teule A, Duran I, Fuster J, Sevilla I, Escudero P, Sastre J, Garcia-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Diez JJ, Carrato A, Garcia-Carbonero R. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) dagger. Ann Oncol Off J Eur Soc Med Oncol. 2015. doi:10.1093/annonc/mdv252.

    Google Scholar 

  13. Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman E. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(18):Suppl 4043.

    Google Scholar 

  14. Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(14):1551–6. doi:10.1200/JCO.2014.56.2082.

    Article  CAS  Google Scholar 

  15. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(18):Suppl 4504.

    Google Scholar 

  16. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz Jr LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203. doi:science.1200609 [pii] 10.1126/science.1200609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kulke M, Niedzwiecki D, Foster N, Briant Fruth B, Kunz P, Kennecke H, Wolin E, Venook A. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E + B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:Suppl; abstr 4005.

    Google Scholar 

  18. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(20):3403–10. doi:26/20/3403 [pii] 10.1200/JCO.2007.15.9020.

    Article  CAS  Google Scholar 

  19. Kunz PL, Kuo T, Zhan JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford M, Balise RR, Fisher GA. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol. 2010;28:15s Suppl; abstr 4104.

    Google Scholar 

  20. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–6.

    Article  CAS  PubMed  Google Scholar 

  21. Kvols LK, Oberg KE, O’Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–66. doi:10.1530/ERC-11-0367.

    Google Scholar 

  22. Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):173–85, ix. doi:10.1016/j.ecl.2010.12.003.

    Article  CAS  PubMed  Google Scholar 

  23. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246–54.

    Article  CAS  PubMed  Google Scholar 

  24. Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg. 1993;17(4):504–10.

    Article  CAS  PubMed  Google Scholar 

  25. Maurer R, Reubi JC. Somatostatin receptors. JAMA. 1985;253(18):2741.

    Article  CAS  PubMed  Google Scholar 

  26. O’Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Blumberg J, Ruszniewski P. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–6. 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 [pii].

    Article  PubMed  Google Scholar 

  27. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12. doi:S0140-6736(11)61742-X [pii] 10.1016/S0140-6736(11)61742-X.

    Article  CAS  PubMed  Google Scholar 

  28. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16(6):695–703. doi:10.1016/S1470-2045(15)70136-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. doi:10.1056/NEJMoa1003825.

    Article  CAS  PubMed  Google Scholar 

  30. Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol. 1997;11(8):1062–9.

    Article  CAS  PubMed  Google Scholar 

  31. Reichlin S. Somatostatin. N Engl J Med. 1983;309(24):1495–501.

    Article  CAS  PubMed  Google Scholar 

  32. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4656–63.

    Article  CAS  Google Scholar 

  33. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155–62. doi:10.1038/nrm3757.

    Article  CAS  PubMed  Google Scholar 

  34. Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend Jr CM, Evers BM. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128(5):1045–56. doi:10.1002/ijc.25441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Stilling GA, Zhang H, Ruebel KH, Leontovich AA, Jin L, Tanizaki Y, Zhang S, Erickson LA, Hobday T, Lloyd RV. Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors. Endocr Pathol. 2007;18(4):223–32. doi:10.1007/s12022-007-9001-3.

    Article  CAS  PubMed  Google Scholar 

  36. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16(24):2963–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013;20(3):383–90. doi:10.1530/ERC-12-0390.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32(2):133–8.

    Article  CAS  PubMed  Google Scholar 

  39. Venook AP, Ko AH, Tempero MA, Uy J, Weber T, Korn M, EK B. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol. 2008;26:15_Suppl 15545, 26(15):Suppl 15545.

    Google Scholar 

  40. Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, Weissman H, Palmer DH, Vora J, Pritchard DM, Cuthbertson DJ. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108(7):1440–8. doi:10.1038/bjc.2013.103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2(12):999–1017.

    Article  CAS  PubMed  Google Scholar 

  42. Wolin E, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse M, Tomassetti P, Weber M, Fogelman D, Ramage J, Poon D, Huang J, Hudson M, Zhi X, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Oberg K. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors with disease-related symptoms inadequately controlled by somatostatin analogs. J Clin Oncol Off J Am Soc Clin Oncol. 2013;(31):Suppl;abstr 4031.

    Google Scholar 

  43. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84.

    Article  CAS  PubMed  Google Scholar 

  44. Yao J, Guthrie K, Moran C, Strosberg J, Kulke M, Chan J, LoConte N, McWilliams R, Wolin E, Mattar B, McDonough S, Chen H, Blanke C, Hochster H. SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:Suppl;abstr 4004.

    Google Scholar 

  45. Yao J, Phan A, Fogelman D, Ng C, Jacobs C, Dagohoy C, Leary C, Hess K. Randomized run-in study of bevacizumab and everolimus in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(15):Suppl 4002.

    Google Scholar 

  46. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):69–76. doi:JCO.2009.24.2669 [pii] 10.1200/JCO.2009.24.2669.

    Article  CAS  Google Scholar 

  47. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(8):1316–23.

    Article  CAS  Google Scholar 

  48. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. doi:10.1056/NEJMoa1009290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FOB 2nd Floor, 12902 Magnolia Ave, Tampa, FL, 33612, USA

    Heloisa Prado Soares MD, PhD & Jonathan Strosberg MD

  2. Oncologic Sciences, University of South Florida, Tampa, FL, USA

    Heloisa Prado Soares MD, PhD & Jonathan Strosberg MD

  3. Neuroendocrine Program, Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Jonathan Strosberg MD

Authors
  1. Heloisa Prado Soares MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Strosberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heloisa Prado Soares MD, PhD .

Editor information

Editors and Affiliations

  1. Diagnostic & Experimental Pathology Lilly Res Laboratories, Eli Lilly & Co., Indianapolis, Indiana, USA

    Aejaz Nasir

  2. H. Lee Moffitt Cancer Ctr & Res, University of South Florida, Tampa, Florida, USA

    Domenico Coppola

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Soares, H.P., Strosberg, J. (2016). Targeted Therapies for Neuroendocrine Neoplasms. In: Nasir, A., Coppola, D. (eds) Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3426-3_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3426-3_28

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3424-9

  • Online ISBN: 978-1-4939-3426-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation